TIMP2 and acute kidney injury: While these two examples employ well-validated risk-stratification tools (i.e., RAI) and biomarkers (i.e., uNGAL and [TIMP2]●[IGFBP7]) in their respective populations, additional population-specific examples of emerging, yet-to-be widely validated risk stratification tools for pediatric AKI also exist [15–23].